Purpose of this study is to determine the types, incidence, and severity of acute complications of intracranial stereotactic radiosurgery (SRS), specifically Gamma Knife (GK). Patients who had never had previous SRS were eligible for this prospective IRB-approved study. The questionnaire used applicable questions from CTCAE v.3.0, the Brief Pain Questionnaire (Short Form), Brief Fatigue Inventory, and the Tinnitus Handicap Inventory. Questionnaires were obtained prior to Gamma Knife (GK), 1 week, 1 month, and 2 months to assess complications. Seventy-six eligible patients (median age of 62 years) had complete data and were analyzed. Diagnoses included: 26 (34%) with brain metastases, 15 (20%) with trigeminal neuralgia, 12 (16%) with schwannoma, 10 (13%) with meningioma, 7 (9%) with arteriovenous malformation, 3 (4%) with pituitary adenoma, and 3 (4%) with other. At 1 week, 24% developed minimal scalp numbness (p 5 0.0004 baseline compared to 1 week). Only 13% had minimal scalp numbness at 1 month and 2% at 2 months (both p 5 NS compared to baseline). There was no difference in scalp tingling between baseline and the various time points. Thirteen percent developed pin site pain at 1 week with a median intensity level of 2 out of 10. By one month, only 3% had pin site pain with a median intensity level of 3 out of 10.
Introduction
Stereotactic radiosurgery (SRS) has become a popular technique for treating both malignant tumors and benign disease of the brain. This is an alternative to surgery and fractionated radiotherapy which have their own toxicities. The advantages of SRS over surgery include 1) outpatient delivery, 2) no requirement for general anesthesia, 3) no incisions are needed which translates into minimal risk for bleeding or infection, 4) lower costs, and 5) short recovery Technology in Cancer Research & Treatment, Volume 11, Number 2, April 2012 time. Three main forms of SRS include: Gamma Knife, linear accelerator (LINAC) based, and particle-based (e.g., proton) radiosurgery. Indications for SRS include brain metastases, vestibular schwannomas, arteriovenous malformations, trigeminal neuralgia, primary brain tumors, meningiomas, glomus jugulare, pituitary adenomas, cluster headaches, Parkinson's disease, obsessive compulsive disorder, and epilepsy (1).
Despite the popularity of SRS, there are limited studies on the acute complications following therapy. Given the paucity of data regarding the acute effects of SRS which may be severe, the goal of this study is to prospectively determine the incidence, time frame, and degree of the short-term complications from SRS, in particular, Gamma Knife. This information would help inform patients and physicians as to the expected acute complications of SRS. It will also educate them regarding to their severity, as well as possible strategies to prevent or treat these side effects.
Materials and Methods

Study Plan and Patient Characteristics
An IRB-approved questionnaire study (Case IRB 8078) was conducted. Patients were eligible if they had not previously undergone SRS. Their life expectancy had to be long enough to complete the study (at least 3 months). They could not participate if they were found to have physical or mental limitations preventing them from answering questions or if they were unwilling to participate in phone interviews. A baseline questionnaire was completed prior to Gamma Knife treatment. Questions pertained to scalp numbness, scalp paresthesias, pain around pin site regions, facial swelling, signs of pin site infection, headache, orbital pain, nausea/vomiting, hair loss, mouth ulcers, fatigue, balance difficulties, tinnitus, new neurological deficits, seizures, syncope, unanticipated emergency room visits, and the patient's ability to work. Pain such as pin site pain, headache, and orbital pain were monitored using the Brief Pain Inventory (Short Form) (2). Care was taken to distinguish pain from the procedure versus pain secondary to the disease process. Fatigue was assessed using the Brief Fatigue Inventory (3), Tinnitus was documented using the Tinnitus Handicap Inventory (4). Repeat questionnaires were obtained at 1-2 weeks, 1 month, and 2 months following Gamma Knife radiosurgery. These questionnaires were completed via phone or mail. All patients gave informed consent. Figure 1 illustrates the schema of this study.
The SRS procedure involved placement of an IV. Versed 0.5 to 2 mg was typically given. The head frame is placed with the assistance of an index box. Local anesthetic (1% lidocaine or 9 cc 1% lidocaine miexed with 1 cc sodium bicarbonate) was placed at the pin sites. Pins were placed and secured until finger tight. The frame was checked to make sure no pins were loose, before final tightening of the pins. CT, MRI, and in some cases, angiograms were obtained. Patients were planned using the GammaPlan® system (version 5.3; Elekta, Norcross, GA). Once the plan was generated and approved by the neurosurgeon, radiation oncologist, and radiation physicist, the treatment was conducted per plan on Gamma Knife® Model 4C (Elekta). All patients received dexamethasone 10 mg IV. Once completed, the head frame was removed and patients were discharged with home going instructions.
Statistics
Parametric one-sided paired binomial sample size calculations determined that 74 patients would be needed to detect an increase in new and worsening deficits incidence of 25% from baseline to 1 week (25% incidence estimated by the PI, using incidence as the primary outcome of this study). A Bonferroni adjustment of alpha 0.05 was done by dividing alpha by 3, which equaled 0.0166 (3 comparisons for incidence outcome: baseline to 1 week, 1 week to 1 month, 1 week to 2 months), resulting in a sample size of 74 patients. Power was equal to 80%. To adjust for a non-parametric test, we calculated 74 patients multiplied by 15% and added it to the previous total. Seventy-four plus 11 equaled 85 assessable patients. [The value of 15% to convert from parametric to nonparametric was taken from Nonparametrics: Statistical Methods Based on Ranks (5)].
Comparisons of baseline to each of the time periods were analyzed using the Wilcoxon Signed Rank test. When 3 intervals were compared, Bonferroni's correction was implemented, resulting in a p-value , 0.0166 as significant.
Results
A total of 95 patients were consented. Of these, a total of 76 evaluable patients were enrolled onto the study. Nineteen patients were lost either due to not proceeding with Gamma Knife or being lost to follow-up. The median age was 62 years old (range: 18-90). Table I summarizes the patient diagnoses.
One week after GK, 24% of patients reported minimal scalp numbness, not interfering with function and 1% reported mild scalp numbness, interfering with function, but not activities of daily living (p 5 0.0004 baseline compared to 1 week). At one and two months, 13% and 2% reported minimal scalp numbness, respectively (p 5 NS compared to baseline for both intervals). Figure 2 summarizes this data.
Thirteen percent developed pin site pain at 1 week with a median intensity level of 2 out of 10. By one month, only 3% had pin site pain with a median intensity level of 3 out of 10. Four percent reported pin-site infection at 1 week and none at 1 and 2 months. (Figure 2 ). No significant difference in nausea from baseline was noted at 1 week, but there was worsening nausea at 1 month (p 5 0.0114). By 1 month, 10% reported new local hair loss. 23%, 16%, and 15% complained of new/worsening fatigue at 1 week, 1 month, and 2 months, respectively, but 40% reported fatigue at baseline (p 5 NS for all 3 comparisons). This is summarized in Figure 3 . Balance improved following Gamma Knife over all time periods (for all comparisons, p , 0.009). 1%, 6%, and 3% developed new tinnitus at 1 week, 1 month, and 2 months, respectively, which was significant when comparing baseline to non-baseline (p 5 0.0269).
Thirty-two patients were employed prior to Gamma Knife. Three (9%) patients did not return to work. Twenty-seven (84%) patients returned to work a median of 4 days after Gamma Knife. Two people did not report their employment status after Gamma Knife. There was no significant difference in scalp tingling, face swelling, headache, eye pain, vomiting, seizures, or syncopal episode at any intervals compared to baseline.
Discussion
Despite the popularity of stereotactic radiosurgery (SRS), there are few studies that address the potential acute complications following this procedure. In one retrospective study of 78 patients (6), 35% (28 patients) experienced immediate side effects from SRS or stereotactic radiotherapy. The side effects were mild in 87% and consisted of nausea, dizziness/vertigo, seizures, and new persistent headaches. Moderate side effects occurred in 4 (14%) patients and included worsening neurological deficits and orbital pain. Two (7%) patients experienced severe side effects requiring hospitalization for seizure or worsening neurological deficit. The incidence of side effects varied with diagnosis. The group of patients with the most immediate side effect was those with vestibular schwannomas (VS); 50% of these patients developed an immediate side effect. Brain metastases patients had the least immediate side effects with only 21% developing symptoms following SRS or SRT. 33% of VS patients developed dizziness or vertigo which was significantly higher than all other diagnoses as a whole (p , 0.01). The high rates of side effects in this study are contrary to our experience in patients with VS, which was recently published (7).
Days after gamma
Another retrospective study of 835 patients focused on acute complications following Gamma Knife (8). Only eighteen (2.2%) patients developed a neurological complication or death within 7 days of treatment. Twelve (1.4%) had seizures, 5 (0.6%) had new neurological deficits and 3 (0.4%) died. The authors concluded that complications following Gamma Knife are rare. None of our patients had seizures following SRS. This may be due to the fact that we usually put our patients on steroids for at least 10 days for intraaxial lesions. At our institution, all patients with brain metastases are given a steroid taper post radiosurgery, many of which were on steroids prior to SRS. It is infrequent for us to give a steroid taper for patients with benign tumors or functional disorders.
A prospective study of 65 patients was performed in England to investigate adverse effects 2-3 weeks post-Gamma Knife (9). Of the 65 patients, only 47 (72%) were reachable by phone. 64% developed side effects following Gamma Knife. Most of these (91%) were mild to moderate. Common complaints included headache, pin-site pain/ numbness, new/worsening neurological deficits, tiredness, nausea/vomiting, and balance disturbance. Table II lists the frequency of symptoms following Gamma Knife. There was also some suggestion that larger lesions were associated with more serious acute side effects, but this was not statistically significant.
The main side effects noted in our prospective study were scalp numbness, which developed in 24% of the patients. About half of these resolved by 1 month and almost all resolved by 2 months. Patients also had pin site pain which was present 1-2 weeks after the procedure, with most improving 1 month after Gamma Knife. The pain was relatively mild, only measuring 2-3 out of 10.
In a majority of patients, fatigue following radiosurgery was less common than prior to radiosurgery. Forty percent had fatigue symptoms at baseline which decreased to approximately 20% in subsequent questionnaires. While it is difficult to study fatigue in this population given multiple comorbid issues (concurrent chemotherapy, depression regarding diagnosis, anxiety regarding upcoming procedure), SRS does not appear to increase the rate of fatigue. The same issue applies for nausea given comorbid issues. Balance did improve although tinnitus did worsen, possibly due to vestibular schwnnoma patients, although it is not clear due to limitations in our data.
Patients tolerated Gamma Knife well and were able to return to work. Of the 32% who were employed prior to Gamma Knife radiosurgery, 91% returned to work with 84% returning to work within 4 days after the procedure.
Based on this prospective study, GK is well-tolerated with minimal acute side effects, many of which were due to the head frame. The frame-based approach offers higher precision (10) compared to a frameless approach (11), which may be more critical for benign and functional disease. None of the patients developed major side effects that required an unanticipated office visit or admission. None of the patients reported any new neurological symptoms secondary to the Gamma Knife procedure. Table III summarizes the various publications regarding acute complications following SRS.
The limitations of this prospective study include the selective nature of the patient population chosen for this study. Many patients (66%) had benign disease and those with malignant disease had to be healthy enough to answer questions during follow-up phone calls/visits. This may not be the typical patient population seen at some centers. However, choosing this population does help eliminate confusion with potential co-morbidities that would make this study more complex to interpret. 0 5 none, 1 5 minimal, not interfering with function, 2 5 mild, interfering with function, but not ADL, 3 5 moderate, interfering with ADL, 4 5 severe, disabling) 5) Any pin-site infections? (Y/N) 6) Any new headaches? (Y/N) (If yes, use Brief Pain Inventory-Short Form) 7) Any new pain around the orbit/eye (excluding that from pin site)? (Y/N) (If yes, use Brief Pain Inventory-Short Form) 8) Any new nausea? (Please rate: 0 5 none, 1 5 loss of appetite without alteration in eating habits, 2 5 oral intake decreased without significant weight loss, dehydration, or malnutrition; IV fluids indicated ,24 hours, 3 5 inadequate oral intake; IV fluids, tube feedings, or TPN indicated 24 hours, 4 5 life threatening consequences, 5 5 death) 9) Any new vomiting? (When? Please rate: 0 5 none, 1 5 1 episode in 24 hours, 2 5 2-5 episodes in 24 hours; IV fluids indicated ,24 hours, 3 5 6 episodes in 24 hours; IV fluids or TPN indicated 24 hours, 4 5 life threatening consequences, 5 5 death) 10) Any new hair loss? (0 5 None, 1 5 Local, 2 5 General) Also, please rate: 0 5 none, 2 5 one brief generalized seizure; seizure(s) well controlled by anticonvulsants or infrequent motor seizures not interfering with ADL, 3 5 seizures in which consciousness is altered; poorly controlled seizure disorder, with breakthrough generalized seizures despite medical intervention, 4 5 seizures of any kind which are prolonged, repetitive, or difficult to control (e.g., status epilepticus, intractable epilepsy, 5 5 death)) 17) Any new episodes of passing out? (If yes, how many episodes? Also, please rate: 0 5 none, 3 5 present, 4 5 life threatening consequence, 5 5 death) 18) Any need to go to the emergency room or unanticipated admissions to the hospital? (Y/N) (If yes, why and how long was the stay (in days)?) 19) Any other new symptoms? (Y/N) (If yes, describe the symptom(s)) 20) Were you working at a job before the Gamma Knife procedure? (Y/N) (If yes, have you been able to return to your job? How long after Gamma Knife did you return to your job (in days)?) 
